MX2022015968A - Terapia con anticuerpos anti ccr8: biomarcadores y terapias combinadas. - Google Patents

Terapia con anticuerpos anti ccr8: biomarcadores y terapias combinadas.

Info

Publication number
MX2022015968A
MX2022015968A MX2022015968A MX2022015968A MX2022015968A MX 2022015968 A MX2022015968 A MX 2022015968A MX 2022015968 A MX2022015968 A MX 2022015968A MX 2022015968 A MX2022015968 A MX 2022015968A MX 2022015968 A MX2022015968 A MX 2022015968A
Authority
MX
Mexico
Prior art keywords
antibodies
methods
conjugates
generation
tools
Prior art date
Application number
MX2022015968A
Other languages
English (en)
Inventor
Mark Trautwein
Uwe Gritzan
Christian Votsmeier
Beatrix Stelte-Ludwig
Sandra Berndt
Ernst Weber
Nikolaus Pawlowski
Philipp Ellinger
Sabine Hoff
Katharina Filarsky
Ahsen Oliver Von
Wiebke Maria Nadler
Helge Roider
Pascale Buchmann
Christian Bertling
Su - Yi Tseng
Pedro Paz
Phaik Lyn Oh
Patrick Jones
Matyas Gorjanacz
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of MX2022015968A publication Critical patent/MX2022015968A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a herramientas y métodos para la generación de anticuerpos que específicamente se unen a receptores quimiocina, tal como receptores quimiocina CC o CXC. Se proporcionan polipéptidos sulfatados aislados y conjugados de los mismos, que se pueden usar por ejemplo como antígenos o para clasificación inespecífica para facilitar la generación de anticuerpos del receptor de quimiocina anti-humanos, anti-cynomolgus, y/o anti-ratón, por ejemplo para la generación de anticuerpos con CDRs totalmente humanas y/u otras propiedades favorables para uso terapéutico. La presente invención además se refiere a anticuerpos y conjugados de los mismos que pueden obtenerse aplicando las herramientas y métodos antes mencionados. Se proporcionan anticuerpos que específicamente se unen a CCR8 humano, cynomolgus y/o murino con propiedades favorables para uso terapéutico, tal como anticuerpos de reactividad cruzada, anticuerpos totalmente humanos, anticuerpos de internalización baja (incluyendo no-internalización), y anticuerpos que eficientemente inducen ADCC y/o ADCP en células Treg. También se proporcionan usos médicos de los anticuerpos de la invención o conjugados y/o métodos de tratamiento que comprenden la administración de estos anticuerpos a un paciente o sujeto, ya sea solo o en combinación. Biomarcadores, métodos de estratificación y métodos de diagnóstico son finalmente proporcionados para pronosticar o evaluar la capacidad de respuesta a monoterapia de anticuerpo anti-CCR8 o terapia de combinación. La invención además proporciona herramientas y métodos para producir los anticuerpos anteriores, composiciones farmacéuticas, usos diagnósticos de los anticuerpos, y kits con instrucciones para usar.
MX2022015968A 2020-06-26 2021-06-25 Terapia con anticuerpos anti ccr8: biomarcadores y terapias combinadas. MX2022015968A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202062705434P 2020-06-26 2020-06-26
US202062705608P 2020-07-07 2020-07-07
EP20205426 2020-11-03
PCT/EP2021/067580 WO2021260210A2 (en) 2020-06-26 2021-06-25 Anti ccr8 antibody therapy: biomarkers & combination therapies

Publications (1)

Publication Number Publication Date
MX2022015968A true MX2022015968A (es) 2023-01-24

Family

ID=76553783

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2022015954A MX2022015954A (es) 2020-06-26 2021-06-25 Anticuerpos ccr8 para aplicaciones terapeuticas.
MX2022015968A MX2022015968A (es) 2020-06-26 2021-06-25 Terapia con anticuerpos anti ccr8: biomarcadores y terapias combinadas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2022015954A MX2022015954A (es) 2020-06-26 2021-06-25 Anticuerpos ccr8 para aplicaciones terapeuticas.

Country Status (14)

Country Link
US (3) US11427640B1 (es)
EP (5) EP4172201A2 (es)
JP (5) JP2023531990A (es)
KR (2) KR20230028780A (es)
CN (6) CN116234825A (es)
AU (2) AU2021212327A1 (es)
BR (2) BR112022026208A2 (es)
CA (3) CA3188146A1 (es)
CL (1) CL2022003747A1 (es)
IL (2) IL298910A (es)
MX (2) MX2022015954A (es)
PE (1) PE20231200A1 (es)
TW (1) TW202216771A (es)
WO (5) WO2021260208A2 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4103285A2 (en) 2020-02-14 2022-12-21 Jounce Therapeutics, Inc. Antibodies and fusion proteins that bind to ccr8 and uses thereof
JP2023546121A (ja) 2020-10-16 2023-11-01 ラノバ メディシンズ リミテッド 抗ｃｃｒ８モノクローナル抗体およびその使用
JPWO2022211046A1 (es) 2021-03-31 2022-10-06
IL308808A (en) * 2021-06-04 2024-01-01 Amgen Inc Antibodies against CCR8 and their uses
WO2023010054A1 (en) 2021-07-27 2023-02-02 Abbvie Inc. Anti-ccr8 antibodies
CN118176210A (zh) * 2021-08-20 2024-06-11 高诚生物医药公司 抗ccr8抗体及其用途
WO2023076983A1 (en) 2021-10-28 2023-05-04 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
AU2022376954A1 (en) 2021-10-29 2024-05-02 Gilead Sciences, Inc. Cd73 compounds
CA3239784A1 (en) * 2021-12-02 2023-06-08 Lishan Kang Ccr8 antigen binding unit and uses thereof
WO2023122581A2 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
CA3237577A1 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
TW202346277A (zh) 2022-03-17 2023-12-01 美商基利科學股份有限公司 Ｉｋａｒｏｓ鋅指家族降解劑及其用途
WO2023205719A1 (en) 2022-04-21 2023-10-26 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2023230473A1 (en) 2022-05-24 2023-11-30 Bristol-Myers Squibb Company Antibodies that bind to human ccr8
WO2023240135A2 (en) 2022-06-07 2023-12-14 Actinium Pharmaceuticals, Inc. Bifunctional chelators and conjugates
WO2023245074A2 (en) * 2022-06-14 2023-12-21 Purdue Research Foundation Car-expressing pluripotent stem cell-derived neutrophils loaded with drug nanoparticles and uses thereof
US20240116928A1 (en) 2022-07-01 2024-04-11 Gilead Sciences, Inc. Cd73 compounds
WO2024026400A2 (en) * 2022-07-27 2024-02-01 Varian Medical Systems, Inc. Therapeutic combinations of titr effectors with radiation therapy
WO2024052517A2 (en) * 2022-09-09 2024-03-14 Bayer Aktiengesellschaft Medical use of ccr8 antibodies and dosing schedule
WO2024062082A1 (en) 2022-09-21 2024-03-28 Domain Therapeutics Anti-ccr8 monoclonal antibodies and their therapeutic use
WO2024062076A1 (en) 2022-09-21 2024-03-28 Domain Therapeutics Anti-ccr8 monoclonal antibodies and their therapeutic use
WO2024059909A1 (en) * 2022-09-21 2024-03-28 Monash University Anti-ccr8 antibodies
WO2024062072A2 (en) 2022-09-21 2024-03-28 Domain Therapeutics Anti-ccr8 monoclonal antibodies and their therapeutic use
WO2024077239A1 (en) * 2022-10-07 2024-04-11 Genentech, Inc. Methods of treating cancer with anti-c-c motif chemokine receptor 8 (ccr8) antibodies
WO2024088346A1 (en) * 2022-10-28 2024-05-02 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-ccr8 antibodies and uses thereof
WO2024097741A1 (en) * 2022-11-04 2024-05-10 Gilead Sciences, Inc. Anticancer therapies using anti-ccr8 antibody, chemo and immunotherapy combinations
WO2024109657A1 (zh) * 2022-11-22 2024-05-30 上海宏成药业有限公司 抗ccr8抗体及其用途
CN117285627B (zh) * 2023-09-06 2024-06-14 百济神州(上海)生物科技有限公司 抗ccr8抗体及其用途

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US6329510B1 (en) * 1999-01-29 2001-12-11 Millennium Pharmaceuticals, Inc. Anti-CCR1 antibodies and methods of use therefor
JP2003530325A (ja) 2000-03-31 2003-10-14 イーペーエフ ファルマシューティカルス ゲゼルシャフト ミット ベシュレンクテル ハフツング 好ましくは特異的ケモカインレセプター分析、及びケモカインレセプター／リガンド相互作用の助けによる、腫瘍及び炎症細胞の細胞表面プロテオームの調査、並びに腫瘍疾患及び炎症性疾患の治療のための診断薬及び薬剤
AU2003229753A1 (en) 2002-05-13 2003-11-11 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with chemokine receptor 8 (ccr8)
US20080260744A1 (en) * 2002-09-09 2008-10-23 Omeros Corporation G protein coupled receptors and uses thereof
US20050266009A1 (en) * 2003-06-30 2005-12-01 Savient Pharmaceuticals, Inc. Antibodies and uses thereof
US20050069955A1 (en) * 2003-06-30 2005-03-31 Daniel Plaksin Antibodies and uses thereof
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
DK2801583T3 (en) 2004-07-10 2018-07-16 Fox Chase Cancer Center Genetically modified human natural killer cell lines
WO2007044756A2 (en) 2005-10-11 2007-04-19 Icos Corporation Monoclonal antibodies recognizing human ccr8
CN101720368A (zh) 2007-03-09 2010-06-02 中国抗体制药有限公司 储备多样性最大化的功能性人化抗体文库之构建及应用
GB0904214D0 (en) * 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
AR076284A1 (es) 2009-04-29 2011-06-01 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
AU2010297580B2 (en) 2009-09-22 2014-07-31 Probiogen Ag Process for producing molecules containing specialized glycan structures
US20150370960A1 (en) * 2014-03-27 2015-12-24 Massachusetts Institute Of Technology Water-soluble membrane proteins and methods for the preparation and use thereof
US10087259B1 (en) 2014-04-28 2018-10-02 Memorial Sloan Kettering Cancer Center Depleting tumor-specific tregs
KR20170005142A (ko) * 2014-05-27 2017-01-11 아카데미아 시니카 증진된 항체 효능을 위한 범용 당형태에 관한 조성물 및 방법
MA41176A (fr) 2014-12-17 2017-10-24 Bayer As Complexes radio-pharmaceutiques
MX2018001596A (es) * 2015-08-10 2018-05-02 Pepmab B V Anticuerpos anti-receptor ccr7 humanizados.
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
CA3023980A1 (en) 2016-05-16 2017-11-23 Checkmab S.R.L. Markers selectively deregulated in tumor-infiltrating regulatory t cells
CN109475600A (zh) 2016-06-17 2019-03-15 瓦里安医疗系统公司 免疫调节剂与辐射治疗组合
WO2018112033A1 (en) 2016-12-13 2018-06-21 President And Fellows Of Harvard College Methods and compositions for targeting tumor-infiltrating tregs
ES2776926T3 (es) * 2017-03-29 2020-08-03 Shionogi & Co Composición medicinal para tratamiento del cáncer
EP3746079A1 (en) 2018-01-31 2020-12-09 Bayer Aktiengesellschaft Antibody drug conjugates (adcs) with nampt inhibitors
WO2019157098A1 (en) 2018-02-06 2019-08-15 Advaxis, Inc. Compositions comprising a recombinant listeria strain and an anti-ccr8 antibody and methods of use
BR112020025718A2 (pt) 2018-06-18 2021-04-06 Bayer Aktiengesellschaft Conjugados de ligante/agente ativo direcionados contra cxcr5, tendo aglutinantes enzimaticamente cliváveis e perfil de atividade melhorado
CN110835374A (zh) * 2018-08-19 2020-02-25 普米斯生物技术(苏州)有限公司 抗ccr8×ctla-4双特异性抗体及其应用
US20210393692A1 (en) 2018-11-13 2021-12-23 Memorial Sloan Kettering Cancer Center Compositions and methods for adoptive cell therapy for cancer
BR112021011431A2 (pt) * 2018-12-27 2021-11-23 Univ Osaka Anticorpo monoclonal ou um fragmento de anticorpo do mesmo que se liga ao ccr8, seu uso, bem como composição farmacêutica, polinucleotídeo, vetor de expressão e kit
WO2021142002A1 (en) * 2020-01-06 2021-07-15 Vaccinex, Inc. Anti-ccr8 antibodies and uses thereof
EP4103285A2 (en) * 2020-02-14 2022-12-21 Jounce Therapeutics, Inc. Antibodies and fusion proteins that bind to ccr8 and uses thereof
EP4114862A2 (en) 2020-03-05 2023-01-11 Memorial Sloan Kettering Cancer Center Anti-ccr8 agents
IL296673A (en) 2020-03-23 2022-11-01 Bristol Myers Squibb Co Anti-ccr8 antibodies for cancer treatment
JPWO2022004760A1 (es) 2020-06-30 2022-01-06
WO2022003156A1 (en) 2020-07-02 2022-01-06 Oncurious Nv Ccr8 non-blocking binders
EP4175949A4 (en) 2020-07-03 2024-02-28 Nanjing Immunophage Biotech Co Ltd METHODS AND COMPOSITIONS FOR TARGETING TREGS USING CCR8 INHIBITORS
CN113881681B (zh) 2020-09-11 2023-10-13 百奥赛图(北京)医药科技股份有限公司 Ccr8基因人源化非人动物及其构建方法和应用

Also Published As

Publication number Publication date
IL298896A (en) 2023-02-01
CA3188146A1 (en) 2021-12-30
EP4172201A2 (en) 2023-05-03
JP2023531990A (ja) 2023-07-26
CN116096750A (zh) 2023-05-09
BR112022026121A2 (pt) 2023-01-17
EP4171602A2 (en) 2023-05-03
WO2021260210A2 (en) 2021-12-30
EP4172204A2 (en) 2023-05-03
CA3188138A1 (en) 2021-08-05
US20220363768A1 (en) 2022-11-17
EP4171601A2 (en) 2023-05-03
WO2021260209A2 (en) 2021-12-30
WO2021260206A2 (en) 2021-12-30
IL298910A (en) 2023-02-01
MX2022015954A (es) 2023-01-24
AU2021212327A1 (en) 2023-01-05
WO2021260209A3 (en) 2022-03-10
WO2021260208A2 (en) 2021-12-30
CN116096395A (zh) 2023-05-09
JP2023531989A (ja) 2023-07-26
CN116096749A (zh) 2023-05-09
WO2021260208A3 (en) 2022-03-17
TW202216771A (zh) 2022-05-01
WO2021152186A2 (en) 2021-08-05
WO2021260206A3 (en) 2022-03-17
JP2023531991A (ja) 2023-07-26
EP4172202A2 (en) 2023-05-03
BR112022026208A2 (pt) 2023-01-17
CN117653725A (zh) 2024-03-08
CL2022003747A1 (es) 2023-05-19
CA3188142A1 (en) 2021-12-30
PE20231200A1 (es) 2023-08-17
WO2021260210A3 (en) 2022-04-14
CN116096748A (zh) 2023-05-09
US11427640B1 (en) 2022-08-30
AU2021295721A1 (en) 2023-01-19
CN116234825A (zh) 2023-06-06
WO2021152186A3 (en) 2021-12-02
JP2023531988A (ja) 2023-07-26
KR20230028780A (ko) 2023-03-02
KR20230028453A (ko) 2023-02-28
JP2023531705A (ja) 2023-07-25
US20230250178A1 (en) 2023-08-10

Similar Documents

Publication Publication Date Title
MX2022015968A (es) Terapia con anticuerpos anti ccr8: biomarcadores y terapias combinadas.
US20220135675A1 (en) Anti-tim-3 antibodies and use thereof
Staflin et al. Target arm affinities determine preclinical efficacy and safety of anti-HER2/CD3 bispecific antibody
ES2864756T3 (es) Dosificación y administración de anticuerpos anti-CD40 no fucosilados
US20150307620A1 (en) Linked immunotherapeutic agonists that costimulate multiple pathways
JP2014512812A5 (es)
JP2020515247A (ja) 抗ｏｘ４０抗体およびその使用
CL2012001387A1 (es) Anticuerpos murinos, humanizados o fragmentos de ellos anti-receptor epha2; conjugados citotoxicos; composiciones farmaceuticas que los contienen; secuencias nucleotidicas; vector; celula huesped e hibridomas que los producen y el uso de los anticuerpos en el tratamiento del cancer como en metodos de diagnostico. (divisional de sol. n° 2085-07)
SG163615A1 (en) Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
MX2022003249A (es) Anticuerpos anti receptor del factor de necrosis tumoral 2 (tnfr2) y métodos de uso.
RU2013139267A (ru) Улучшенная иммунотерапия
US10981996B1 (en) Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
EP3119806A1 (en) Il-21 antibodies
CN115916199A (zh) 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案
MX2022001403A (es) Metodos de administracion de anticuerpos anti-siglec-8 y corticosteroides.
IT201800000534A1 (it) Procedimenti per la promozione della crescita cellulare degli isolotti pancreatici.
RU2767063C2 (ru) Комбинации и их использование
WO2021087368A3 (en) Anti-cd45 antibodies and conjugates thereof
CN112703038A (zh) 靶向CD38和TGF-β的抗癌组合疗法
WO2019217455A1 (en) Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
AR122763A1 (es) Anticuerpos ccr8 para aplicaciones terapéuticas
CN115803027A (zh) 治疗细胞因子相关的不良事件的方法
IT202100027929A1 (it) Un nuovo anticorpo bispecifico asimmetrico(UMG2/CD1a-CD3e) per il trattamento immunologico della forma corticale di leucemia linfoblastica acuta T (T-ALL) pediatrica e dell’adulto
WO2023227644A3 (en) Anti-cd44v6 antibodies and their use to treat cd44v6 overexpressing cancers
KR20220159989A (ko) C19 c38 이중특이적 항체